In 2020, Credo Biomedical debuted its rapid flu test in the international arena. This series looks at the challenges that fledgling ventures face if they choose to go global and why some companies take the leap. Follow the founders of each company as they navigate key goals and examine whether they succeed in meeting the real-time challenges of product development and sales that they set for themselves.
Credo Preps MDx System, Multiplex Respiratory Test for US Launch
September 20, 2024
NEW YORK – Singapore-based Credo Diagnostics Biomedical is preparing to start US clinical trials fora new near-patient point-of-care molecular diagnostic system and multiplex respiratory test. The company
